OpenBilldrug price receipt

NADAC week of 2026-10-14

PIOGLITAZONE-GLIMEPIRIDE 30-2

For 30 tablets

Pharmacies pay

$322.79 filed

30 × $10.75973 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-08-19 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$147.04 filed

30 × $4.90144 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

0.46× estimated

Medicare paid 54% less than pharmacies pay.

Part D averages every strength and form sold under “Pioglitazone-Glimepiride” / “Pioglitazone HCl/Glimepiride” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-08-19 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$376.21 estimated

$322.79 + $48.42 (15%) + $5.00 fee per fill = $376.21

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-08-19 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

PIOGLITAZONE-GLIMEPIRIDE 30-2 is how the CMS NADAC file names this product. The FDA NDC Directory lists it as pioglitazone and glimepiride.

FDA gives its dosage form as tablet and its route as oral.

The labeler, the company named on the label, is Prasco Laboratories.

FDA lists it under 4 Established Pharmacologic Classes: Peroxisome Proliferator Receptor alpha Agonist, Peroxisome Proliferator Receptor gamma Agonist, Sulfonylurea and Thiazolidinedione.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 66993-0821-30.

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $322.79 for 30 tablets (30 × $10.75973 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-08-19. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 4, carried forward from the previous file; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.

This NDC’s NADAC was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: it took effect on 2026-08-19. The file is new; the price is not.

The NDC

Other strengths, forms and brands

1 other product in the NADAC file shares the FDA nonproprietary name pioglitazone and glimepiride with PIOGLITAZONE-GLIMEPIRIDE 30-2.

ProductPharmacies pay per unitMedicare per unit
PIOGLITAZONE-GLIMEPIRIDE 30-2 this page
generic · tablet
$10.75973 per EA filed
eff. 2026-08-19
$4.90144 per EA filed
Part D 2024 average
PIOGLITAZONE-GLIMEPIRIDE 30-4
generic · tablet
$10.51761 per EA filed
eff. 2026-09-23
$4.90144 per EA filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-08-19, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

Its NADAC price is $10.75973 per EA filed.

Of the 23 other products in FDA’s Peroxisome Proliferator Receptor alpha Agonist class priced per EA, 1 has a higher middle NADAC price and 22 a lower one. The one in the middle is FENOFIBRATE 200 MG CAPSULE, at $0.16437 per EA filed (eff. 2026-09-23).

Of the 7 other products in FDA’s Peroxisome Proliferator Receptor gamma Agonist class priced per EA, 0 have a higher middle NADAC price and 7 a lower one. The one in the middle is PIOGLITAZONE-METFORMIN 15-850, at $0.23908 per EA filed (eff. 2026-09-23).

Of the 20 other products in FDA’s Sulfonylurea class priced per EA, 0 have a higher middle NADAC price and 20 a lower one. The one in the middle is GLIPIZIDE ER 2.5 MG TABLET, at $0.09927 per EA filed (eff. 2026-09-23).

Of the 7 other products in FDA’s Thiazolidinedione class priced per EA, 0 have a higher middle NADAC price and 7 a lower one. The one in the middle is PIOGLITAZONE-METFORMIN 15-850, at $0.23908 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-08-19, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $147.04 for 30 tablets, at an average of $4.90144 per EA in 2024 (2024-01-01 to 2024-12-31) for “Pioglitazone-Glimepiride” and “Pioglitazone HCl/Glimepiride”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 3,586 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for PIOGLITAZONE-GLIMEPIRIDE 30-2 labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Pioglitazone-Glimepiride / Pioglitazone HCl/Glimepiride: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.